Slide 1: 2023 Full Year Results
2023 Full Year Results 30 May 2024
Slide 2: Presenters
Presenters Lyn Rees, Chief Executive Officer Steve Gibson, Chief Financial Officer • CEO of Novacyt Group since 1 May 2024 • Joined Novacyt in 2017 • 6 years as CEO of Yourgene Health • Group Finance Director since February 2020, • Drove the acquisition of Elucigene Diagnostics CFO since January 202
Slide 3: What we do
What we do International molecular diagnostics company with a growing portfolio of clinical assays, instrumentation and research tools. With deep focus and expertise across reproductive health, precision medicine and infectious disease. Clinical IVD assays & Research qPCR kits Instruments for qPCR D
Slide 4: Novacyt Group Established global footprint
Novacyt Group Established global footprint Locations: • UK - Manchester – Southampton – Stokesley • Miami, USA • Taipei, Taiwan • Singapore • Canada • Commercial presence in over 65 countries Headquartered in Vélizy in France Listed on the: • London Stock Exchange's AIM market ("NCYT") • Paris Stock
Slide 5: 2023 Audited Full Year Results
2023 Audited Full Year Results © Novacyt Group of companies
Slide 6: Operational highlights
Operational highlights Business Development Strengthened Board • Strategic acquisition of Yourgene • Lyn Rees, CEO Health • Steve Gibson, CFO • Yourgene became a compatible • Dr Jo Mason, CSO partner of PacBio • John Brown, Non-Executive Director IVDR Certification Product Development • Received acc
Slide 7: 2023 Audited –Income Statement
2023 Audited –Income Statement Continuing operations 2023 2022 ❖ Group revenue totalled £11.6m in line with guidance, following decline in COVID- £'000 £'000 19-related sales Revenue 11,579 21,040 Gross profit 3,730 5,746 ❖ Group gross margin increased to 32% Gross profit % 32% 27% (£3.7m), due to C
Slide 8: 2023 Audited - Statement of Financial Position
2023 Audited - Statement of Financial Position Assets Dec-23 Dec-22 Equity and Liabilities Dec-23 Dec-22 £'000 £'000 £'000 £'000 Goodwill 21,446 6,646 Share capital and premium 54,586 54,633 Right-of-use assets 11,036 521 Retained earnings and reserves 32,656 60,583 Property, plant and equipment 4,1
Slide 9: Trading update: January-April 2024
Trading update: January-April 2024 ❖ Group revenue totalled £6.9m, 73% of sales generated by Yourgene Health ❖ Completed actions that will deliver annual cost reductions of over £4.0m ❖ Continue to look at further opportunities to right size the cost base of the Group ❖ Cash at the end of April was
Slide 10: Integration update
Integration update © Novacyt Group of companies
Slide 11: Integration update
Integration update Utilising the strengthened expertise within the combined leadership team Broader technology portfolio, with a stronger end-to-end customer offering Enhanced routes to market in Europe, Asia and the Americas - Rationalised, high quality distribution network Refocused Primer Design
Slide 12: Business reorganisation
Business reorganisation Clinical Instrumentation Research Use Only IVD products, workflows DNA size selection and and services rapid PCR Reproductive Health: Ranger® Technology High-performance qPCR assays • NIPT • Next generation size selection and workflows • Cystic Fibrosis for cell-free DNA • Hu
Slide 13: Targeting large and growing addressable markets
Targeting large and growing addressable markets Reproductive Health Precision Medicine Ranger® Technology NIPT DPYD screening • Opportunities across multiple • Favourable national markets • c.2m patients p/a treated with reimbursement policies fluoropyrimidine chemotherapy • National routine screeni
Slide 14: Strategy and growth drivers
Strategy and growth drivers Current Progress Future milestones • New NIPT laboratory customers across Europe, Asia • Growth of NIPT, CF and DPYD with Drive global and South America increased adoption of screening • Launched MagBench in APAC / Middle East • Consumable uptake for Ranger® sales • Stron
Slide 15: Laying the foundations for future growth
Laying the foundations for future growth International molecular diagnostics company with deep focus and expertise across reproductive health, precision medicine and infectious disease Acquisition of Yourgene Health enhanced the Group’s global diagnostics capabilities and added scale and diversifica
Slide 16: info@novacyt.com novacyt.com Novacyt Group (UK)
info@novacyt.com novacyt.com Novacyt Group (UK) York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG, UK T +44 (0)2380 748 830